v3.22.2.2
Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Sep. 30, 2021
Current assets:    
Cash, cash equivalents and restricted cash $ 108,005,000 $ 184,434,000
Accounts receivable 1,410,000 10,255,000
Short-term investments 268,391,000 56,627,000
Marketable securities 0 126,728,000
Prepaid expenses 7,289,000 4,362,000
Other current assets 20,204,000 2,191,000
Total current assets 405,299,000 384,597,000
Property and equipment, net 110,297,000 48,675,000
Intangible assets, net 11,962,000 13,663,000
Long-term investments 105,872,000 245,595,000
Right-of-use assets 58,291,000 17,346,000
Other assets 218,000 272,000
Total Assets 691,939,000 710,148,000
Current liabilities:    
Accounts payable 2,868,000 9,457,000
Accrued expenses 46,856,000 14,001,000
Accrued payroll and benefits 12,251,000 9,773,000
Lease liabilities 2,776,000 2,250,000
Deferred revenue 74,099,000 111,055,000
Total current liabilities 138,850,000 146,536,000
Long-term liabilities:    
Lease liabilities, net of current portion 78,800,000 23,295,000
Deferred revenue, net of current portion 55,950,000 131,495,000
Total long-term liabilities 134,750,000 154,790,000
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders' equity:    
Common stock, $0.001 par value: Authorized 145,000 shares; issued and outstanding 105,960 and 104,327 shares 198,000 197,000
Additional paid-in capital 1,219,213,000 1,053,386,000
Accumulated other comprehensive loss (136,000) (69,000)
Accumulated deficit (820,755,000) (644,692,000)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity 398,520,000 408,822,000
Noncontrolling interest 19,819,000 0
Total noncontrolling interest and stockholders' equity 418,339,000 408,822,000
Total Liabilities, Noncontrolling Interest and Stockholders' Equity $ 691,939,000 $ 710,148,000